1-4 of 4
Alan Wilhelm
Close
Sort by
Journal Articles

IMGN779, a Next Generation CD33-Targeting ADC, Combines Effectively with Cytarabine in Acute Myeloid Leukemia (AML) Preclinical Models, Resulting in Increased DNA Damage Response, Cell Cycle Arrest and Apoptosis In Vitro and Prolonged Survival In Vivo

Sharlene Adams, Meghan Kelly, Rebecca McCarthy, Alan Wilhelm, Krystal Watkins, Leanne Lanieri, Callum M. Sloss, Angela Romanelli
Journal: Blood
Blood (2017) 130 (Supplement 1): 1357.
https://doi.org/10.1182/blood.V130.Suppl_1.1357.1357
Published: 2017
Journal Articles

A CD123-Targeting Antibody-Drug Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid Leukemia (AML) Cells While Sparing Normal Bone Marrow Cells

Yelena Kovtun, PhD, Gregory Jones, Charlene Audette, Lauren Harvey, MS, Baudouin Gerard, PhD, Alan Wilhelm, Chen Bai, Sharlene Adams, PhD, Victor S Goldmacher, PhD, Ravi Chari, PhD, Thomas Chittenden, PhD
Journal: Blood
Blood (2016) 128 (22): 768.
https://doi.org/10.1182/blood.V128.22.768.768
Published: 2016
Journal Articles

IMGN632: A CD123-Targeting Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is Highly Active and Prolongs Survival in Acute Myeloid Leukemia (AML) Xenograft Models

Sharlene Adams, PhD, Alan Wilhelm, Lauren Harvey, MS, Chen Bai, Nicholas Yoder, PhD, Yelena Kovtun, PhD, Thomas Chittenden, PhD, Jan Pinkas, PhD
Journal: Blood
Blood (2016) 128 (22): 2832.
https://doi.org/10.1182/blood.V128.22.2832.2832
Published: 2016
Journal Articles

The Antibody-Drug Conjugate (ADC) IMGN779 Is Highly Active in Vitro and in Vivo Against Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations

Kathleen R Whiteman, MS, Paul Noordhuis, PhD, Russell Walker, MS, Krystal Watkins, MS, Yelena Kovtun, PhD, Lauren Harvey, BS, Alan Wilhelm, BS, Holly Johnson, BS, Gerrit Jan Schuurhuis, PhD, Gert J Ossenkoppele, MD PhD, Robert J. Lutz, PhD
Journal: Blood
Blood (2014) 124 (21): 2321.
https://doi.org/10.1182/blood.V124.21.2321.2321
Published: 2014